Heart International最新文献_第10页

Use of Stent Enhancement Technique During Percutaneous Coronary Intervention - A Case Series. 在经皮冠状动脉介入治疗中使用支架增强技术--一个病例系列。

IF 1.9

Heart International Pub Date : 2019-10-11 eCollection Date: 2019-01-01 DOI: 10.17925/HI.2019.13.1.28

Filippo Figini, Yves Louvard, Imad Sheiban

引用次数: 0

Improved Dosing and Administration of Rivaroxaban when Prescribed by a Cardiologist. 改进利伐沙班的剂量和管理时，由心脏病专家开出。

IF 0.2

Heart International Pub Date : 2019-10-11 eCollection Date: 2019-01-01 DOI: 10.17925/HI.2019.13.1.24

Madeline R Leiter, Kathleen A Packard, Yongyue Qi, Steven K Krueger

{"title":"Improved Dosing and Administration of Rivaroxaban when Prescribed by a Cardiologist.","authors":"Madeline R Leiter, Kathleen A Packard, Yongyue Qi, Steven K Krueger","doi":"10.17925/HI.2019.13.1.24","DOIUrl":"https://doi.org/10.17925/HI.2019.13.1.24","url":null,"abstract":"Rivaroxaban is a direct oral anticoagulant (DOAC) indicated to reduce risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF). A discrepancy exists between the recommended dosage and real-world use of DOACs, especially rivaroxaban, thus putting patients at risk of thromboembolic events.Methods: This retrospective study assessed real-world prescribing and patient adherence to dietary requirements during use of rivaroxaban in 116 patients with AF. Associations between prescriber specialty and the correct dosing and administration were assessed using the Chi-Square test.Results: Most rivaroxaban prescriptions were ordered by cardiologists (50.9%). Sixty-nine patients (59.5%) were taking the right dose at the correct time with an adequate meal. Of the 47 (40.5%) taking rivaroxaban incorrectly, 39 (33.6%) had not been administered an adequate meal and eight (6.9%) were not prescribed the correct dose. Compared with other prescribers, patients were most likely to be taking the correct dose and administration when prescribed by cardiologists (72.9% versus 45.6%; p=0.003). Patients were least likely to be taking the correct dose and administration when prescribed by primary care providers (44.4% versus 69.0%; p=0.009). This difference was driven by patients who did not take the treatment with an adequate meal.Conclusion: Inappropriate prescribing, administration and non-adherence to DOACs can have devastating consequences. This highlights the importance of formal systematic education of patients prescribed DOACs across the whole health system. Future studies are warranted to explore the impact of non-adherence to rivaroxaban dietary requirements on clinical outcomes.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"13 1","pages":"24-27"},"PeriodicalIF":0.2,"publicationDate":"2019-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562422/pdf/heart-int-13-24.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40664275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

What are the Pathological Concerns and Limitations of Current Drug-coated Balloon Technology? 目前的药物涂层球囊技术存在哪些病理问题和局限性？

IF 1.9

Heart International Pub Date : 2019-10-11 eCollection Date: 2019-01-01 DOI: 10.17925/HI.2019.13.1.15

Yu Sato, Salomé H Kuntz, Dipti Surve, Hiroyuki Jinnouchi, Atsushi Sakamoto, Anne Cornelissen, Renu Virmani, Frank Kolodgie, Aloke V Finn

{"title":"What are the Pathological Concerns and Limitations of Current Drug-coated Balloon Technology?","authors":"Yu Sato, Salomé H Kuntz, Dipti Surve, Hiroyuki Jinnouchi, Atsushi Sakamoto, Anne Cornelissen, Renu Virmani, Frank Kolodgie, Aloke V Finn","doi":"10.17925/HI.2019.13.1.15","DOIUrl":"10.17925/HI.2019.13.1.15","url":null,"abstract":"The use of endovascular therapy for peripheral artery disease and coronary artery disease has increased and spread worldwide and is considered as the foremost, guideline-based invasive treatment. Drug-coated balloons (DCBs) utilise anti-proliferative drugs similar to drug-eluting stents; however, the do not leave any permanent metallic scaffold. Excipients and drug formulations play a crucial role in innovative DCB technologies and allow for treatment of lesions where stents are not suitable. Although the significance of downstream embolic effects after DCB use remains uncertain, several preclinical studies suggest such side effects might pose safety concerns. Recently, a meta-analysis of randomised controlled trials of paclitaxel devices suggested an association between increased mortality and paclitaxel device use. Subsequently, unfavourable criticism of paclitaxel devices attracted much attention and gave rise to a discussion about the safety of such devices. In this review, we will focus on the novel DCB technologies from the standpoint of preclinical studies and clinical trials, as well as discuss current controversies regarding the increase in death rates from paclitaxel-coated DCBs versus control devices seen in a recent meta-analysis of randomised controlled clinical trials.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"13 1","pages":"15-22"},"PeriodicalIF":1.9,"publicationDate":"2019-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524611/pdf/heart-int-13-15.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40664273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Letter from the Editor-in-Chief. 总编辑的来信。

IF 0.2

Heart International Pub Date : 2019-10-11 eCollection Date: 2019-01-01 DOI: 10.17925/HI.2019.13.1.12

Magdi El-Omar

引用次数: 0

European Bifurcation Club Perspectives on Two-stent Techniques - An Interview. 欧洲分支俱乐部对双支架技术的看法-访谈。

IF 0.2

Heart International Pub Date : 2019-09-18 eCollection Date: 2019-01-01 DOI: 10.17925/HI.2019.13.1.9

Dr Francesco Burzotta

引用次数: 0

Role of Optimal Medication Given to Patients with Hypertension and Ischemic Heart Disease Prior to an Acute Coronary Syndrome. 急性冠脉综合征前高血压和缺血性心脏病患者最佳用药的作用

IF 0.2

Heart International Pub Date : 2017-10-14 eCollection Date: 2017-01-01 DOI: 10.5301/heartint.5000237

Călin Pop, Roberta Florescu, Claudia Matei, Lavinia Pop, Viorel Manea, Coralia Cotoraci, Liana Mos, Antoniu Petris

{"title":"Role of Optimal Medication Given to Patients with Hypertension and Ischemic Heart Disease Prior to an Acute Coronary Syndrome.","authors":"Călin Pop, Roberta Florescu, Claudia Matei, Lavinia Pop, Viorel Manea, Coralia Cotoraci, Liana Mos, Antoniu Petris","doi":"10.5301/heartint.5000237","DOIUrl":"https://doi.org/10.5301/heartint.5000237","url":null,"abstract":"Introduction: Administering optimal cardiovascular medication (OCM) to patients with hypertension (HBP) and ischemic heart disease (IHD) lowers cardiovascular morbidity and mortality.The main objective of this study was to compare in-hospital cardiac mortality among patients with HBP and/or IHD, treated or untreated with OCM, who developed a first episode of acute coronary syndrome (ACS).Methods: The study was carried out retrospectively and included patients admitted with a first episode of ACS between 2013 and 2016. The patients were divided into three groups: those with HBP, IHD, and a history of HBP + IHD. Patients were then divided into two subgroups: subgroup A consisted of patients undergoing optimal anti-ischemic and/or antihypertensive therapy, while subgroup B consisted of patients without OCM.Results: This analysis comprised 1096 patients. Mean age was 64.3 ± 18 years. There were 581 patients in subgroup A - 53%, and 515 patients in subgroup B - 47%. Total cardiac mortality was 9.98%, different depending on the groups and subgroups studied: HBP group total - 7%, subgroup A - 5.1%, significantly lower compared to subgroup B - 9.4% (p = 0.05); IHD group total - 12.2%, subgroup A - 9.07%, significantly lower compared to subgroup B - 15.8% (p = 0.05); HBP + IHD group total - 14.35%, subgroup A - 9.9%, significantly lower compared to subgroup B - 18.8% (p = 0.05).Conclusions: The lack of OCM in patients with HBP and/or IHD is correlated to a significant increase in in-hospital cardiac mortality among patients who develop a first-episode ACS.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"12 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2017-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5301/heartint.5000237","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36532120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Mild troponin I elevation does not predict ischemia on myocardial perfusion imaging 轻度肌钙蛋白I升高不能在心肌灌注显像上预测缺血

IF 0.2

Heart International Pub Date : 2017-08-02 DOI: 10.5301/HEARTINT.5000236

L. Ha, Farrukh Abbas, M. Rao

{"title":"Mild troponin I elevation does not predict ischemia on myocardial perfusion imaging","authors":"L. Ha, Farrukh Abbas, M. Rao","doi":"10.5301/HEARTINT.5000236","DOIUrl":"https://doi.org/10.5301/HEARTINT.5000236","url":null,"abstract":"Introduction: Data are limited on the degree of mild troponin I elevation and clinical risk factors in predicting myocardial ischemia. Methods: Hospitalized adult patients who underwent myocardial perfusion imaging (MPI) from 2015 to 2016 at Rochester General Hospital and had mild troponin I elevation (>0.1 and <1.5 ng/mL) were included. Predictors of outcomes were determined using logistic regression model. Results: One hundred and sixty-six patients with mild troponin I elevation who underwent MPI were followed. Mean age was 69.6 ± 12.5 years and 53.0% of the patients were female. Fourteen patients (8.4%) presented with typical chest pain (CP), 60 patients (36.1%) had atypical CP and 92 patients (55.4%) had no CP on presentation. MPI was positive for ischemia in 45 patients (27.1%). There was no difference in peak troponin I level with ischemia versus no ischemia on MPI (0.34 ng/dL [0.13-0.69] vs. 0.23 ng/dL [0.14-0.50], p value 0.254). Atypical CP did not predict the presence of ischemia on MPI (odds ratio [OR] 1.97, 95% confidence interval [CI] 0.91-4.26). Coronary artery disease (CAD) history (age and sex adjusted p value 0.013), diabetes (adjusted p value 0.036), creatinine ≥2 mg/dL (adjusted p value 0.019) and dialysis (adjusted p value 0.006) were statistically significant predictors of ischemia on MPI. Conclusions: In patients presenting with mild troponin I elevation, peak troponin I level did not predict ischemia on MPI. The presence of CAD history, diabetes, elevated creatinine and dialysis were predictors of ischemia on MPI.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"12 1","pages":"0-0"},"PeriodicalIF":0.2,"publicationDate":"2017-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46510802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Placement Of Cardiac PacemaKEr Trial (POCKET) - rationale and design: a randomized controlled trial. 心脏起搏器放置试验(POCKET) -基本原理和设计:一项随机对照试验。

IF 0.2

Heart International Pub Date : 2017-04-14 eCollection Date: 2017-01-01 DOI: 10.5301/heartint.5000235

Peter Magnusson, Leo Wennström, Robert Kastberg, Per Liv

{"title":"Placement Of Cardiac PacemaKEr Trial (POCKET) - rationale and design: a randomized controlled trial.","authors":"Peter Magnusson, Leo Wennström, Robert Kastberg, Per Liv","doi":"10.5301/heartint.5000235","DOIUrl":"https://doi.org/10.5301/heartint.5000235","url":null,"abstract":"Background: A pacemaker system consists of one or two leads connected to a device that is implanted into a pocket formed just below the collarbone. This pocket is typically subcutaneous, that is, located just above the pectoral fascia. Even though the size of pacemakers has decreased markedly, complications due to superficial implants do occur. An alternative technique would be intramuscular placement of the pacemaker device, but there are no randomized controlled trials (RCTs) to support this approach, which is the rationale for the Placement Of Cardiac PacemaKEr Trial (POCKET). The aim is to study if intramuscular is superior to subcutaneous placement of a pacemaker pocket.Methods: In October 2016, we started to enroll 200 consecutive patients with an indication for bradycardia pacemaker implantation. Patients are randomized to random block sizes, stratified by age group (cut-off: 65 years) and sex, and then randomized to either subcutaneous or intramuscular implant. A concealed allocation procedure is employed, using sequentially numbered, sealed envelopes. Pocket site is blinded to the patient and in all subsequent care. The primary endpoint is patient overall satisfaction with the pocket location at 24 months as measured using a visual analog scale (VAS) 0-10. Secondary endpoints are: complications, patient-reported satisfaction at 1, 12, and 24 months (overall satisfaction, pain, discomfort, degree of unsightly appearance, movement problems, and sleep problems due to device).Conclusions: POCKET is a prospective interventional RCT designed to evaluate if intramuscular is superior to subcutaneous placement of a bradycardia pacemaker during a two-year follow-up.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"12 1","pages":"e8-e11"},"PeriodicalIF":0.2,"publicationDate":"2017-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5301/heartint.5000235","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35585980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9

The inhibitory effects of polysaccharide peptides (PsP) of Ganoderma lucidum against atherosclerosis in rats with dyslipidemia. 灵芝多糖肽(PsP)对血脂异常大鼠动脉粥样硬化的抑制作用。

IF 0.2

Heart International Pub Date : 2017-04-12 eCollection Date: 2017-01-01 DOI: 10.5301/heartint.5000234

Titin Andri Wihastuti, Teuku Heriansyah

{"title":"The inhibitory effects of polysaccharide peptides (PsP) of Ganoderma lucidum against atherosclerosis in rats with dyslipidemia.","authors":"Titin Andri Wihastuti, Teuku Heriansyah","doi":"10.5301/heartint.5000234","DOIUrl":"https://doi.org/10.5301/heartint.5000234","url":null,"abstract":"Background: Atherosclerosis occurs as a result of low-density lipoprotein (LDL) deposits oxidation. Endothelial dysfunction is an early process of atherosclerosis. Restoring endothelial lining back to normal by endothelial progenitor cells (EPCs) is critical for slowing or reversing vascular disease progression. Oxidative stress from hydrogen peroxide (H2O2) is increased in dyslipidemia so that antioxidant agent is required to prevent destruction of blood vessels.Objectives: This study aims to report Ganoderma lucidum polysaccharide peptide (PsP) effects in atherogenic process by measuring H2O2 level, IL-10 level, and EPC number in blood serum, and also intima-media thickness of aorta in dyslipidemia Wistar rat model by giving them a hypercholesterol diet (HCD).Materials and methods: The study was an experimental in vivo post-test with control group design. Thirty-five Wistar rats (Rattus norwegicus) were divided into five groups (normal diet group, HCD group, and hypercholesterol groups that received 50 mg/kg, 150 mg/kg, and 300 mg/kg bodyweight PsP).Results: Each treatment group showed significant results for the administration of PsP using the one-way analysis of variance test (p<0.050) for the reduction of H2O2 (p = 0.003), levels of IL-10 (p = 0.027), number of EPC in the blood serum (p = 0.011), and the intima-media thickness of the aorta (p = 0.000). PsP from G. lucidum is a potent antioxidant and may prevent atherogenesis process in patients with dyslipidemia.Conclusions: The optimum doses of PsP in this study is 300 mg/kg bodyweight. Further studies are required to determine the antioxidant effects of PsP G. lucidum and its benefits in the management of dyslipidemia.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"12 1","pages":"e1-e7"},"PeriodicalIF":0.2,"publicationDate":"2017-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5301/heartint.5000234","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35585978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

Calculating the 30-day Survival Rate in Acute Myocardial Infarction: Should we Use the Treatment Chain or the Hospital Catchment Model? 计算急性心肌梗死的30天生存率:我们应该使用治疗链还是医院集水区模型?

IF 0.2

Heart International Pub Date : 2017-02-12 eCollection Date: 2017-01-01 DOI: 10.5301/heartint.5000238

Jan Norum, Tonya M Hansen, Anders Hovland, Lise Balteskard, Bjørn Haug, Frank Olsen, Thor Trovik

{"title":"Calculating the 30-day Survival Rate in Acute Myocardial Infarction: Should we Use the Treatment Chain or the Hospital Catchment Model?","authors":"Jan Norum, Tonya M Hansen, Anders Hovland, Lise Balteskard, Bjørn Haug, Frank Olsen, Thor Trovik","doi":"10.5301/heartint.5000238","DOIUrl":"https://doi.org/10.5301/heartint.5000238","url":null,"abstract":"Introduction: Acute myocardial infarction (AMI) is a potentially deadly disease and significant efforts have been concentrated on improving hospital performance. A 30-day survival rate has become a key quality of care indicator. In Northern Norway, some patients undergoing AMI are directly transferred to the Regional Cardiac Intervention Center at the University Hospital of North Norway in Tromsø. Here, coronary angiography and percutaneous coronary intervention is performed. Consequently, local hospitals may be bypassed in the treatment chain, generating differences in case mix, and making the treatment chain model difficult to interpret. We aimed to compare the treatment chain model with an alternative based on patients' place of living.Methods: Between 2013 and 2015, a total of 3,155 patients were registered in the Norwegian Patient Registry database. All patients were categorized according to their local hospital's catchment area. The method of Guo-Romano, with an indifference interval of 0.02, was used to test whether a hospital was an outlier or not. We adjusted for age, sex, comorbidity, and number of prior hospitalizations.Conclusions: We revealed the 30-day AMI survival figure ranging between 88.0% and 93.5% (absolute difference 5.5%) using the hospital catchment method. The treatment chain rate ranged between 86.0% and 94.0% (absolute difference 8.0%). The latter figure is the one published as the National Quality of Care Measure in Norway. Local hospitals may get negative attention even though their catchment area is well served. We recommend the hospital catchment method as the first choice when measuring equality of care.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"12 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2017-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5301/heartint.5000238","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36532121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1